



Trend of OPDIVO

Sales Trend of OPDIVO by Each Cancer




Prescription Ratio in Patients Newly Treated* for 1L ESC(Squamous Cell Carcinoma)



*Patients starting treatment within the last 3 month

Source: Primary research results
(May 2022~Apr 2025: n=150~155)

Prescription Ratio in Patients Newly Treated* for 1L NSCLC




*Patients starting 1L treatment within the last 1 month (Except Driver Mutation)

Source: Primary research results
(Nov 2020~Apr 2025: n=167~245)

The result of Clinical Study - NSCLC 1L (PD-L1 negative) -



CheckMate 9LA Trial



OPDIVO + YERVOY + Chemo

Five-year overall survival rates


22%

Six-year overall survival rates

20%

Carbone DP, et al. ESMO Open. 2025 Jun;10(6):105123

CheckMate 227 Trial



OPDIVO + YERVOY

Five-year overall survival rates

19%

Six-year overall survival rates

16%

The Clinical Trial Result of HCC 1L



CheckMate 9DW Trial

	OPDIVO + YERVOY	Control Group (molecular-targeted drug)
OS	23.7 months	20.6 months
PFS	9.1 months	9.2 months
ORR	36%	13%
DOR	30.4 months	12.9 months
Three-years overall survival rates (follow-up data)	38%	24%
Steroid	29%*	-
Treatment-related death	3.6%	0.9%

* Percentage of high-dose steroid use

Lancet. 2025 May 24;405(10492):1851-1864.



ONO PHARMACEUTICAL CO.,LTD.

Dedicated to the Fight against Disease and Pain